Dyne Therapeutics, Inc.

DYN · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions103.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	–	–	$963.00M	$1.18B
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$468.18M	-$343.89M	-$170.96M	-$150.03M	-$58.65M	–	–	-$236.00M	-$11.00M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$446.21M	-$317.42M	-$168.10M	-$149.29M	-$59.44M	-$356.00M	–	-$1.65B	$0
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-3.00	$-3.00	$-2.93	$-4.13	–	–	$-13.48	$-1.95
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-3.00	$-3.00	–	–	–	–	$-13.48	$-1.95

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$893.37M	$435.45M	$172.15M	$200.82M	$300.85M	$843.00M	–	$396.00M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.19B	$691.23M	$306.32M	$425.66M	–	–	–	–	–
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	$1.99B	$1.39B	$588.00M	$4.57B
Everything the company owes — debt, unpaid bills, and other obligations.	$214.83M	$61.40M	$53.96M	$57.47M	–	–	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$972.13M	$629.84M	$252.36M	$368.20M	–	–	–	–	–

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$403.21M	-$292.37M	-$153.65M	-$119.56M	-$46.51M	–	–	-$20.00M	$423.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.92M	$2.38M	$3.07M	$3.62M	$1.16M	–	–	$242.00M	$333.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$405.13M	-$294.75M	-$156.71M	-$123.18M	-$47.67M	–	–	-$262.00M	$90.00M

	You	Peer avg
P/E	–	12.6
Revenue Growth	–	-15.9%
ROE	-81.6%	-478.2%

Dyne Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison